Medicament for improving efficacy of oral helicobacter pylori vaccine and use thereof

A Helicobacter pylori and vaccine technology, which is applied in the direction of medical preparations containing active ingredients, antibacterial drugs, drug combinations, etc., can solve the problem of short duration, vaccines are easily destroyed by gastric acid, and vaccines cannot exert immune effects in the intestinal tract, etc. problem, to achieve the effect of improving efficiency

Active Publication Date: 2021-09-24
CHENGDU OLYMVAX BIOPHARM
View PDF6 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In order to protect the antigenic components in the oral Helicobacter pylori vaccine from being destroyed by gastric acid, the commonly used pre-immunization treatment method is: 30 minutes before immunization, orally administer 0.3mL gastric acid neutralizing solution to the rats. This method has a weak inhibitory effect on gastric acid, and the duration Short, gavage vaccines are easily destroyed by gastric acid, so that the vaccine cannot exert immune effects in the intestinal tract, which is not conducive to the research and evaluation of Helicobacter pylori vaccines through oral gavage, and hinders the preclinical research of Helicobacter pylori vaccines

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicament for improving efficacy of oral helicobacter pylori vaccine and use thereof
  • Medicament for improving efficacy of oral helicobacter pylori vaccine and use thereof
  • Medicament for improving efficacy of oral helicobacter pylori vaccine and use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] Example 1 Detection of gastric juice pH value in Balb / c mice after intraperitoneal injection of proton pump inhibitors

[0031] 6-week-old female Balb / c mice, 18g±2g, 20 in total. Rats were grouped by random grouping method after purchase, 10 rats / cage. The feeding conditions are: feeding in a normal-grade environment, the temperature is 22±4°C, the humidity is 55±10%. For disinfection, the feed was conventional feed, and the water was obtained by autoclaving after being prepared by a pure water instrument, and they had free access to food and water.

[0032] After 7 days of transitional feeding, the mouse gastric juice pH value detection experiment was performed, and the mouse gastric juice pH value detection scheme was as follows:

[0033] Draw solution A with a sterile syringe, and inject 250 uL of solution A into each mouse by intraperitoneal injection; the composition of solution A: 0.1 mg omeprazole / mouse, and the solvent is sterile saline. 30min, 45min, 60min,...

Embodiment 2

[0039] Liquid residence time in the stomach after oral gavage of Balb / c mice in embodiment 2

[0040] 6-week-old female Balb / c mice, 18g±2g, 20 in total. Rats were grouped by random grouping method after purchase, 10 rats / cage. The feeding conditions are: feeding in a normal-grade environment, the temperature is 22±4°C, the humidity is 55±10%. For disinfection, the feed was conventional feed, and the water was obtained by autoclaving after being prepared by a pure water instrument, and they had free access to food and water.

[0041] After 7 days of transitional feeding, the oral gavage experiment was carried out, and the liquid residence time in the stomach after oral gavage of Balb / c mice was tested:

[0042] Draw physiological saline with a gavage needle, and each mouse is orally gavaged with 0.3mL; 2min, 4min, 6min, 8min, 10min, 12min, 14min, 16min, 18min, 20min after the end of gavage, detect the liquid residue and excretion in the mouse stomach. Empty situation; 2 mic...

Embodiment 3

[0049] Preparations before oral Helicobacter pylori vaccine:

[0050] 6-week-old female Balb / c mice, 18g±2g, 20 in total. After the mice were purchased, the mice were grouped by random grouping method, 10 mice / cage. The feeding conditions are: feeding in a normal-grade environment, the temperature is 22±4°C, the humidity is 55±10%. For disinfection, the feed was conventional feed, and the water was obtained by autoclaving after being prepared by a pure water instrument, and they had free access to food and water. Immunization experiments were carried out 1 day after transitional feeding.

[0051] The composition of the Helicobacter pylori vaccine is as follows: A1 protein 2.5mg / mL, solvent: 1.17% sodium chloride, 0.03% sodium carbonate, 0.18% sodium bicarbonate, 5mL / 100mL glycerol, and the pH of the solution is 8.5.

[0052] Before immunization, the Helicobacter pylori vaccine was taken out from -80°C and thawed in a 4°C refrigerator for later use.

[0053] The Helicobacte...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a medicament for improving efficacy of an oral helicobacter pylori vaccine and use thereof, and belongs to the technical field of vaccine development. The oral helicobacter pylori vaccine comprises an A1 protein, sodium chloride, sodium carbonate, sodium bicarbonate, glycerol and water. When a proton pump inhibitor is used before the oral helicobacter pylori vaccine is used, a pH value of gastric juice of a mouse can be neutral, and the helicobacter pylori vaccine can be effectively protected from being damaged by gastric acid. The medicament breaks through a bottleneck that a positive conversion rate of oral immunization saliva titer detection is zero and lays a foundation for the helicobacter pylori vaccine to exert an immune effect in intestinal tracts.

Description

technical field [0001] The invention belongs to the technical field of vaccine development, and in particular relates to a medicament for improving the efficacy of an oral Helicobacter pylori vaccine and an application thereof. Background technique [0002] Helicobacter pylori (Hp) in my country's "Fifth National Consensus Report on the Treatment of Helicobacter pylori Infection" in 2017 has about 4.4 billion infected people worldwide, with an average infection rate of 62.8%; about 50% in my country (about 50% in children) 30%), and the number of infections is as high as 768 million. Helicobacter pylori can be transmitted from person to person. It is an infectious disease and an infectious disease. At present, the treatment of Helicobacter pylori adopts antimicrobial therapy. During the long-term treatment, the drug resistance of Helicobacter pylori gradually increased, and the eradication rate dropped to 73.5% in 2012. So far, no H. pylori vaccine has been marketed. [00...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/4439A61K39/02A61P1/04A61P31/04
CPCA61K31/4439A61K39/0208A61P31/04A61P1/04A61K2039/542Y02A50/30
Inventor 杜方川童文德朱白梅童武学王茂莉
Owner CHENGDU OLYMVAX BIOPHARM
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap